Philip Van Damme

List of Publications by Year
in descending order

313 papers	21,205 citations	7568 77 h-index	13771 129 g-index
333 all docs	333 docs citations	333 times ranked	21460 citing authors

#	Article	IF	Citations
1	A modified Camel and Cactus Test detects presymptomatic semantic impairment in genetic frontotemporal dementia within the GENFI cohort. Applied Neuropsychology Adult, 2022, 29, 112-119.	1.2	18
2	RNF170 mutation causes autosomal dominant sensory ataxia with variable pyramidal involvement. European Journal of Neurology, 2022, 29, 345-349.	3.3	2
3	A data-driven disease progression model of fluid biomarkers in genetic frontotemporal dementia. Brain, 2022, 145, 1805-1817.	7.6	27
4	Stratifying the Presymptomatic Phase of Genetic Frontotemporal Dementia by Serum <scp>NfL</scp> and <scp>pNfH</scp>: A Longitudinal Multicentre Study. Annals of Neurology, 2022, 91, 33-47.	5.3	21
5	Genome-wide identification of the genetic basis of amyotrophic lateral sclerosis. Neuron, 2022, 110, 992-1008.e11.	8.1	51
6	Structural variation analysis of 6,500 whole genome sequences in amyotrophic lateral sclerosis. Npj Genomic Medicine, 2022, 7, 8.	3.8	23
7	The importance of offering early genetic testing in everyone with amyotrophic lateral sclerosis. Brain, 2022, 145, 1207-1210.	7.6	21
8	Electrodiagnosis of Guillain-Barre syndrome in the International GBS Outcome Study: Differences in methods and reference values. Clinical Neurophysiology, 2022, 138, 231-240.	1.5	7
9	Conceptual framework for the definition of preclinical and prodromal frontotemporal dementia. Alzheimer's and Dementia, 2022, 18, 1408-1423.	0.8	24
10	Structural brain splitting is a hallmark of Granulin-related frontotemporal dementia. Neurobiology of Aging, 2022, , .	3.1	1
11	Genome-wide study of DNA methylation shows alterations in metabolic, inflammatory, and cholesterol pathways in ALS. Science Translational Medicine, 2022, 14, eabj0264.	12.4	38
12	Genome-wide association analyses identify new Brugada syndrome risk loci and highlight a new mechanism of sodium channel regulation in disease susceptibility. Nature Genetics, 2022, 54, 232-239.	21.4	55
13	Clinical trials in pediatric ALS: a TRICALS feasibility study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 481-488.	1.7	3
14	Insights into the identification of a molecular signature for amyotrophic lateral sclerosis exploiting integrated microRNA profiling of iPSC-derived motor neurons and exosomes. Cellular and Molecular Life Sciences, 2022, 79, 189.	5.4	12
15	Frontotemporal Lobar Degeneration Case with an N-Terminal TUBA4A Mutation Exhibits Reduced TUBA4A Levels in the Brain and TDP-43 Pathology. Biomolecules, 2022, 12, 440.	4.0	5
16	Whole-genome sequencing reveals that variants in the Interleukin 18 Receptor Accessory Protein 3â€²UTR protect against ALS. Nature Neuroscience, 2022, 25, 433-445.	14.8	16
17	Semantic modelling of common data elements for rare disease registries, and a prototype workflow for their deployment over registry data. Journal of Biomedical Semantics, 2022, 13, 9.	1.6	11
18	Respiratory onset of amyotrophic lateral sclerosis in a pregnant woman with a novel SOD1 mutation. European Journal of Neurology, 2022, 29, 1279-1283.	3.3	2

#	Article	IF	Citations
19	The role of inflammation in neurodegeneration: novel insights into the role of the immune system in C9orf72 HRE-mediated ALS/FTD. Molecular Neurodegeneration, 2022, 17, 22.	10.8	24
20	Prognostic relationship of neurofilaments, CHIT1, YKL-40 and MCP-1 in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 681-682.	1.9	7
21	HDAC3 Inhibition Stimulates Myelination in a CMT1A Mouse Model. Molecular Neurobiology, 2022, 59, 3414-3430.	4.0	7
22	Cellular Stress Induces Nucleocytoplasmic Transport Deficits Independent of Stress Granules. Biomedicines, 2022, 10, 1057.	3.2	5
23	Neuromuscular complications after COVID-19 vaccination: a series of eight patients. Acta Neurologica Belgica, 2022, 122, 753-761.	1.1	9
24	Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease. Neurology, 2022, 99, .	1.1	16
25	Characterising ALS disease progression according to El Escorial and Gold Coast criteria. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 865-870.	1.9	10
26	Brain metabolic changes across Kingâ€™s stages in amyotrophic lateral sclerosis: a 18F-2-fluoro-2-deoxy-d-glucose-positron emission tomography study. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1124-1133.	6.4	10
27	TDP-43 proteinopathies: a new wave of neurodegenerative diseases. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 86-95.	1.9	174
28	PCYT2 mutations disrupting etherlipid biosynthesis: phenotypes converging on the CDP-ethanolamine pathway. Brain, 2021, 144, e17-e17.	7.6	6
29	Necrosomeâ€positive granulovacuolar degeneration is associated with TDPâ€43 pathological lesions in the hippocampus of ALS/FTLD cases. Neuropathology and Applied Neurobiology, 2021, 47, 328-345.	3.2	15
30	Papillary thyroid carcinoma presenting with severe Guillain-BarrÃ© syndrome. Acta Clinica Belgica, 2021, 76, 236-238.	1.2	0
31	The Effect of <scp>SMN</scp> Gene Dosage on <scp>ALS</scp> Risk and Disease Severity. Annals of Neurology, 2021, 89, 686-697.	5.3	10
32	Progression of Behavioral Disturbances and Neuropsychiatric Symptoms in Patients With Genetic Frontotemporal Dementia. JAMA Network Open, 2021, 4, e2030194.	5.9	42
33	Prognostic value of neurofilament light chain in chronic inflammatory demyelinating polyneuropathy. Brain Communications, 2021, 3, fcab018.	3.3	7
34	STING-Induced Inflammation â€" A Novel Therapeutic Target in ALS?. New England Journal of Medicine, 2021, 384, 765-767.	27.0	6
35	C9orf72 ALS-FTD: recent evidence for dysregulation of the autophagy-lysosome pathway at multiple levels. Autophagy, 2021, 17, 3306-3322.	9.1	52
36	Chitotriosidase as biomarker for early stage amyotrophic lateral sclerosis: a multicenter study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 276-286.	1.7	14

#	Article	IF	Citations
37	HDAC6 inhibition restores TDPâ€43 pathology and axonal transport defects in human motor neurons with TARDBP mutations. EMBO Journal, 2021, 40, e106177.	7.8	51
38	AAV9-mediated gene delivery of MCT1 to oligodendrocytes does not provide a therapeutic benefit in a mouse model of ALS. Molecular Therapy - Methods and Clinical Development, 2021, 20, 508-519.	4.1	12
39	C9orf72 -derived arginine-containing dipeptide repeats associate with axonal transport machinery and impede microtubule-based motility. Science Advances, 2021, 7, .	10.3	57
40	Liquidâ€“Liquid Phase Separation Enhances TDP-43 LCD Aggregation but Delays Seeded Aggregation. Biomolecules, 2021, 11, 548.	4.0	18
41	Detection of multiple myositis-specific autoantibodies in unique patients with idiopathic inflammatory myopathy: A single centre-experience and literature review. Seminars in Arthritis and Rheumatism, 2021, 51, 486-494.	3.4	8
42	Altered perivascular fibroblast activity precedes ALS disease onset. Nature Medicine, 2021, 27, 640-646.	30.7	69
43	Distinguishing Primary Lateral Sclerosis from Parkinsonian Syndromes with the Help of Advanced Imaging. Journal of Nuclear Medicine, 2021, 62, 1318-1319.	5.0	1
44	Neuropathy of the phrenic nerve associated with antiganglioside antibodies. European Journal of Neurology, 2021, 28, 2138-2141.	3.3	1
45	The Revised Self-Monitoring Scale detects early impairment of social cognition in genetic frontotemporal dementia within the GENFI cohort. Alzheimer's Research and Therapy, 2021, 13, 127.	6.2	12
46	Tweaking Progranulin Expression: Therapeutic Avenues and Opportunities. Frontiers in Molecular Neuroscience, 2021, 14, 713031.	2.9	28
47	Innovating Clinical Trials for Amyotrophic Lateral Sclerosis. Neurology, 2021, 97, 528-536.	1.1	19
48	Association of Variants in the SPTLC1 Gene With Juvenile Amyotrophic Lateral Sclerosis. JAMA Neurology, 2021, 78, 1236.	9.0	46
49	Human motor units in microfluidic devices are impaired by FUS mutations and improved by HDAC6 inhibition. Stem Cell Reports, 2021, 16, 2213-2227.	4.8	47
50	Psychopathology in premanifest C9orf72 repeat expansion carriers. Journal of Neurology, Neurosurgery and Psychiatry, 2021, , jnnp-2021-327774.	1.9	1
51	Guillain-BarrÃ© syndrome after SARS-CoV-2 infection in an international prospective cohort study. Brain, 2021, 144, 3392-3404.	7.6	39
52	Generation of Human Motor Units with Functional Neuromuscular Junctions in Microfluidic Devices. Journal of Visualized Experiments, 2021, , .	0.3	4
53	Correlations between measures of ALS respiratory function: is there an alternative to FVC?. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 495-504.	1.7	2
54	Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of <scp>REGAIN</scp> and its extension study. Muscle and Nerve, 2021, 64, 662-669.	2.2	11

#	Article	IF	Citations
55	Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS) Tj ETQq1 1 0.784314 rgBT /Overloc 821-831.	10.2	9
56	Differential early subcortical involvement in genetic FTD within the GENFI cohort. NeuroImage: Clinical, 2021, 30, 102646.	2.7	28
57	Histone Deacetylase Inhibition Regulates Lipid Homeostasis in a Mouse Model of Amyotrophic Lateral Sclerosis. International Journal of Molecular Sciences, 2021, 22, 11224.	4.1	27
58	A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcotâ€“Marieâ€“Tooth type 1A. Orphanet Journal of Rare Diseases, 2021, 16, 433.	2.7	23
59	SCFD1 expression quantitative trait loci in amyotrophic lateral sclerosis are differentially expressed. Brain Communications, 2021, 3, fcab236.	3.3	14
60	A panel of CSF proteins separates genetic frontotemporal dementia from presymptomatic mutation carriers: a GENFI study. Molecular Neurodegeneration, 2021, 16, 79.	10.8	9
61	FAIRification Efforts of Clinical Researchers: The Current State of Affairs. Studies in Health Technology and Informatics, 2021, 287, 35-39.	0.3	1
62	Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. Nature Genetics, 2021, 53, 1636-1648.	21.4	223
63	Investigating the Endo-Lysosomal System in Major Neurocognitive Disorders Due to Alzheimerâ€™s Disease, Frontotemporal Lobar Degeneration and Lewy Body Disease: Evidence for SORL1 as a Cross-Disease Gene. International Journal of Molecular Sciences, 2021, 22, 13633.	4.1	8
64	TSPO Versus P2X7 as a Target for Neuroinflammation: An In Vitro and In Vivo Study. Journal of Nuclear Medicine, 2020, 61, 604-607.	5.0	42
65	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. Lancet Neurology, The, 2020, 19, 145-156.	10.2	175
66	RNA-Sequencing Highlights Inflammation and Impaired Integrity of the Vascular Wall in Brain Arteriovenous Malformations. Stroke, 2020, 51, 268-274.	2.0	22
67	Non-invasive characterization of amyotrophic lateral sclerosis in a hTDP-43A315T mouse model: A PET-MR study. NeuroImage: Clinical, 2020, 27, 102327.	2.7	9
68	Placebo effect in chronic inflammatory demyelinating polyneuropathy: The <scp>PATH</scp> study and a systematic review. Journal of the Peripheral Nervous System, 2020, 25, 230-237.	3.1	15
69	TRICALS: creating a highway toward a cure. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 496-501.	1.7	20
70	Rare Variant Burden Analysis within Enhancers Identifies CAV1 as an ALS Risk Gene. Cell Reports, 2020, 33, 108456.	6.4	24
71	Diagnostic yield of testing for RFC1 repeat expansions in patients with unexplained adult-onset cerebellar ataxia. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1233-1234.	1.9	9
72	Consistent improvement with eculizumab across muscle groups in myasthenia gravis. Annals of Clinical and Translational Neurology, 2020, 7, 1327-1339.	3.7	16

#	Article	IF	Citations
73	Dipeptide repeat protein and TDP-43 pathology along the hypothalamicâ€“pituitary axis in C9orf72 and non-C9orf72 ALS and FTLD-TDP cases. Acta Neuropathologica, 2020, 140, 777-781.	7.7	8
74	Use of Multimodal Imaging and Clinical Biomarkers in Presymptomatic Carriers of C9orf72 Repeat Expansion. JAMA Neurology, 2020, 77, 1008.	9.0	45
75	Amyotrophic lateral sclerosis: a clinical review. European Journal of Neurology, 2020, 27, 1918-1929.	3.3	451
76	A multi-center study of neurofilament assay reliability and inter-laboratory variability. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 452-458.	1.7	15
77	Moving Toward Multicenter Therapeutic Trials in Amyotrophic Lateral Sclerosis: Feasibility of Data Pooling Using Different Translocator Protein PET Radioligands. Journal of Nuclear Medicine, 2020, 61, 1621-1627.	5.0	22
78	Neurofilament light chain and C reactive protein explored as predictors of survival in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 436-437.	1.9	25
79	Phase 1â€“2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. New England Journal of Medicine, 2020, 383, 109-119.	27.0	354
80	Myositis as a neuromuscular complication of immune checkpoint inhibitors. Acta Neurologica Belgica, 2020, 120, 355-364.	1.1	17
81	Combined brain and spinal FDG PET allows differentiation between ALS and ALS mimics. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2681-2690.	6.4	15
82	Late-onset Pompe disease (LOPD) in Belgium: clinical characteristics and outcome measures. Orphanet Journal of Rare Diseases, 2020, 15, 83.	2.7	26
83	ATXN1 repeat expansions confer risk for amyotrophic lateral sclerosis and contribute to TDP-43 mislocalization. Brain Communications, 2020, 2, fcaa064.	3.3	33
84	Intracerebroventricular delivery of vascular endothelial growth factor in patients with amyotrophic lateral sclerosis, a phase I study. Brain Communications, 2020, 2, fcaa160.	3.3	16
85	Is there a glucose metabolic signature of spreading TDP-43 pathology in amyotrophic lateral sclerosis?. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2020, 64, 96-104.	0.7	6
86	Knowledge, attitudes and behaviours towards vaccination: a survey of university students in Europe. European Journal of Public Health, 2020, 30, .	0.3	0
87	Quantitative Nucleocytoplasmic Transport Assays in Cellular Models of Neurodegeneration. Bio-protocol, 2020, 10, e3659.	0.4	2
88	Serum neurofilament light chain levels as a marker of upper motor neuron degeneration in patients with Amyotrophic Lateral Sclerosis. Neuropathology and Applied Neurobiology, 2019, 45, 291-304.	3.2	82
89	Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study. Journal of the Neurological Sciences, 2019, 407, 116419.	0.6	18
90	Dystrophin deficiency leads to dysfunctional glutamate clearance in iPSC derived astrocytes. Translational Psychiatry, 2019, 9, 200.	4.8	18

#	Article	IF	Citations
91	Reduction of ephrin-A5 aggravates disease progression in amyotrophic lateral sclerosis. Acta Neuropathologica Communications, 2019, 7, 114.	5.2	11
92	Restoration of histone acetylation ameliorates disease and metabolic abnormalities in a FUS mouse model. Acta Neuropathologica Communications, 2019, 7, 107.	5.2	61
93	P.69NEO1 and NEO-EXT studies: exploratory efficacy of repeat avalglucosidase alfa dosing for up to 5 years in participants with late-onset Pompe disease (LOPD). Neuromuscular Disorders, 2019, 29, S60-S61.	0.6	0
94	C9orf72-generated poly-GR and poly-PR do not directly interfere with nucleocytoplasmic transport. Scientific Reports, 2019, 9, 15728.	3.3	47
95	Phenotypes and malignancy risk of different FUS mutations in genetic amyotrophic lateral sclerosis. Annals of Clinical and Translational Neurology, 2019, 6, 2384-2394.	3.7	49
96	Serum neurofilament heavy chains as early marker of motor neuron degeneration. Annals of Clinical and Translational Neurology, 2019, 6, 1971-1979.	3.7	29
97	A Phase 3 Multicenter, Prospective, Open-Label Efficacy and Safety Study of Immune Globulin (Human) 10% Caprylate/Chromatography Purified in Patients with Myasthenia Gravis Exacerbations. European Neurology, 2019, 81, 223-230.	1.4	23
98	Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e590.	6.0	37
99	Differentiation but not ALS mutations in FUS rewires motor neuron metabolism. Nature Communications, 2019, 10, 4147.	12.8	41
100	Reducing EphA4 before disease onset does not affect survival in a mouse model of Amyotrophic Lateral Sclerosis. Scientific Reports, 2019, 9, 14112.	3.3	10
101	Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies. Journal of the Peripheral Nervous System, 2019, 24, 48-55.	3.1	17
102	Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the preâ€randomization phase of the Polyneuropathy And Treatment with Hizentra study. Journal of the Peripheral Nervous System, 2019, 24, 72-79.	3.1	13
103	Analytical performance of a CE-marked immunoassay to quantify phosphorylated neurofilament heavy chains. Clinical Chemistry and Laboratory Medicine, 2019, 57, e199-e202.	2.3	1
104	Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology, 2019, 92, e2661-e2673.	1.1	169
105	Inflammatory markers in cerebrospinal fluid: independent prognostic biomarkers in amyotrophic lateral sclerosis?. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, jnnp-2018-319586.	1.9	42
106	A phase III trial of tirasemtiv as a potential treatment for amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 584-594.	1.7	29
107	Motor cortex metabolite alterations in amyotrophic lateral sclerosis assessed in vivo using edited and non-edited magnetic resonance spectroscopy. Brain Research, 2019, 1718, 22-31.	2.2	24
108	NEO1 and NEO-EXT studies: Long-term safety of repeat avalglucosidase alfa dosing for 4.5 years in late-onset Pompe disease patients. Molecular Genetics and Metabolism, 2019, 126, S115-S116.	1.1	0

#	Article	IF	Citations
109	An ALS case with 38 (G4C2)-repeats in the C9orf72 gene shows TDP-43 and sparse dipeptide repeat protein pathology. Acta Neuropathologica, 2019, 137, 855-858.	7.7	12
110	Microglia lacking a peroxisomal Î²-oxidation enzyme chronically alter their inflammatory profile without evoking neuronal and behavioral deficits. Journal of Neuroinflammation, 2019, 16, 61.	7.2	20
111	Exome array analysis of rare and low frequency variants in amyotrophic lateral sclerosis. Scientific Reports, 2019, 9, 5931.	3.3	16
112	Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis. Annals of Neurology, 2019, 85, 470-481.	5.3	118
113	Mutations in the Glycosyltransferase Domain of GLT8D1 Are Associated with Familial Amyotrophic Lateral Sclerosis. Cell Reports, 2019, 26, 2298-2306.e5.	6.4	57
114	Clinical spectrum of the anti-GQ1b antibody syndrome: a case series of eight patients. Acta Neurologica Belgica, 2019, 119, 29-36.	1.1	17
115	Longâ€term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle and Nerve, 2019, 60, 14-24.	2.2	162
116	AB0696â€…DETECTION OF COEXISTING MYOSITIS-SPECIFIC AUTOANTIBODIES WITH LINE AND DOT IMMUNOASSAYS IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES. , 2019, , .		0
117	Circadian sleep/wake-associated cells show dipeptide repeat protein aggregates in C9orf72-related ALS and FTLD cases. Acta Neuropathologica Communications, 2019, 7, 189.	5.2	22
118	White matter hyperintensities in progranulin-associated frontotemporal dementia: A longitudinal GENFI study. NeuroImage: Clinical, 2019, 24, 102077.	2.7	27
119	EphA4 loss improves social memory performance and alters dendritic spine morphology without changes in amyloid pathology in a mouse model of Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2019, 11, 102.	6.2	17
120	Lowering EphA4 Does Not Ameliorate Disease in a Mouse Model for Severe Spinal Muscular Atrophy. Frontiers in Neuroscience, 2019, 13, 1233.	2.8	2
121	Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naÃ¯ve and alglucosidase alfa-treated patients with late-onset Pompe disease: A phase 1, open-label, multicenter, multinational, ascending dose study. Neuromuscular Disorders, 2019, 29, 167-186.	0.6	59
122	Association of NIPA1 repeat expansions with amyotrophic lateral sclerosis in a large international cohort. Neurobiology of Aging, 2019, 74, 234.e9-234.e15.	3.1	26
123	Derivation of norms for the Dutch version of the Edinburgh cognitive and behavioral ALS screen. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 19-27.	1.7	17
124	Detection of myositis-specific antibodies. Annals of the Rheumatic Diseases, 2019, 78, e7-e7.	0.9	48
125	FUS (fused in sarcoma) is a component of the cellular response to topoisomerase Iâ€“induced DNA breakage and transcriptional stress. Life Science Alliance, 2019, 2, e201800222.	2.8	20
126	Anterior interosseous mononeuropathy associated with HEV infection. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e429.	6.0	2

#	Article	IF	Citations
127	Intravenous versus subcutaneous immunoglobulin â€“ Authors' reply. Lancet Neurology, The, 2018, 17, 393-394.	10.2	0
128	Conditional deletion of Id2 or Notch1 in oligodendrocyte progenitor cells does not ameliorate disease outcome in SOD1G93A mice. Neurobiology of Aging, 2018, 68, 1-4.	3.1	16
129	How much of the missing heritability of ALS is hidden in known ALS genes?. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 794-794.	1.9	6
130	HDAC6 is a therapeutic target in mutant GARS-induced Charcot-Marie-Tooth disease. Brain, 2018, 141, 673-687.	7.6	93
131	Elongator subunit 3 (ELP3) modifies ALS through tRNA modification. Human Molecular Genetics, 2018, 27, 1276-1289.	2.9	56
132	Inhibition of histone deacetylase 6 (HDAC6) protects against vincristine-induced peripheral neuropathies and inhibits tumor growth. Neurobiology of Disease, 2018, 111, 59-69.	4.4	52
133	A zebrafish model for C9orf72 ALS reveals RNA toxicity as a pathogenic mechanism. Acta Neuropathologica, 2018, 135, 427-443.	7.7	98
134	Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurology, The, 2018, 17, 423-433.	10.2	342
135	Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron, 2018, 97, 1268-1283.e6.	8.1	517
136	Comparison of elevated phosphorylated neurofilament heavy chains in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 367-373.	1.9	86
137	NEK1 genetic variability in a Belgian cohort of ALS and ALS-FTD patients. Neurobiology of Aging, 2018, 61, 255.e1-255.e7.	3.1	32
138	Reconsidering the causality of TIA1 mutations in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 1-3.	1.7	22
139	Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. Neurology, 2018, 90, e22-e30.	1.1	148
140	Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurology, The, 2018, 17, 35-46.	10.2	193
141	REGISTRIES AND CARE OF NEUROMUSCULAR DISORDERS. Neuromuscular Disorders, 2018, 28, S117.	0.6	0
142	Glucose metabolic brain patterns to discriminate amyotrophic lateral sclerosis from Parkinson plus syndromes. EJNMMI Research, 2018, 8, 110.	2.5	7
143	Non-invasive assessment of disease progression and neuroprotective effects of dietary coconut oil supplementation in the ALS SOD1G93A mouse model: A 1H-magnetic resonance spectroscopic study. NeuroImage: Clinical, 2018, 20, 1092-1105.	2.7	14
144	Regional variation of Guillain-BarrÃ© syndrome. Brain, 2018, 141, 2866-2877.	7.6	190

#	Article	IF	Citations
145	Progranulin reduces insoluble TDP-43 levels, slows down axonal degeneration and prolongs survival in mutant TDP-43 mice. Molecular Neurodegeneration, 2018, 13, 55.	10.8	38
146	Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk. Cell, 2018, 175, 1679-1687.e7.	28.9	115
147	Genetic Architecture of Adaptive Immune System Identifies Key Immune Regulators. Cell Reports, 2018, 25, 798-810.e6.	6.4	36
148	FUS-induced neurotoxicity in Drosophila is prevented by downregulating nucleocytoplasmic transport proteins. Human Molecular Genetics, 2018, 27, 4103-4116.	2.9	33
149	Topographical Guidance of PSC-Derived Cortical Neurons. Journal of Nanomaterials, 2018, 2018, 1-10.	2.7	3
150	From lexical regularities to axiomatic patterns for the quality assurance of biomedical terminologies and ontologies. Journal of Biomedical Informatics, 2018, 84, 59-74.	4.3	11
151	Project MinE: study design and pilot analyses of a large-scale whole-genome sequencing study in amyotrophic lateral sclerosis. European Journal of Human Genetics, 2018, 26, 1537-1546.	2.8	129
152	Astrocyte-derived Jagged-1 mitigates deleterious Notch signaling in amyotrophic lateral sclerosis. Neurobiology of Disease, 2018, 119, 26-40.	4.4	35
153	Generation of a human induced pluripotent stem cellâ€“based model for tauopathies combining three microtubuleâ€associated protein TAU mutations which displays several phenotypes linked to neurodegeneration. Alzheimer's and Dementia, 2018, 14, 1261-1280.	0.8	41
154	Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial. Lancet Neurology, The, 2018, 17, 689-698.	10.2	48
155	In Vivo Electrophysiological Measurement of Compound Muscle Action Potential from the Forelimbs in Mouse Models of Motor Neuron Degeneration. Journal of Visualized Experiments, 2018, , .	0.3	12
156	Molecular Dissection of FUS Points at Synergistic Effect of Low-Complexity Domains in Toxicity. Cell Reports, 2018, 24, 529-537.e4.	6.4	74
157	Multicenter validation of [¹⁸F]-FDG PET and support-vector machine discriminant analysis in automatically classifying patients with amyotrophic lateral sclerosis versus controls. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 570-577.	1.7	19
158	No supportive evidence for TIA1 gene mutations in a European cohort of ALS-FTD spectrum patients. Neurobiology of Aging, 2018, 69, 293.e9-293.e11.	3.1	15
159	Diagnostic and Prognostic Performance of Neurofilaments in ALS. Frontiers in Neurology, 2018, 9, 1167.	2.4	100
160	ATXN2 trinucleotide repeat length correlates with risk of ALS. Neurobiology of Aging, 2017, 51, 178.e1-178.e9.	3.1	86
161	Investigating the role of ALS genes CHCHD10 and TUBA4A in Belgian FTD-ALS spectrum patients. Neurobiology of Aging, 2017, 51, 177.e9-177.e16.	3.1	60
162	Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurology, The, 2017, 16, 208-216.	10.2	62

#	Article	IF	Citations
163	C9orf72 expansion differentially affects males with spinal onset amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 281.1-281.	1.9	33
164	Clinical Evidence of Disease Anticipation in Families Segregating a C9orf72 Repeat Expansion. JAMA Neurology, 2017, 74, 445.	9.0	56
165	Prognostic value of clinical and electrodiagnostic parameters at time of diagnosis in patients with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 341-350.	1.7	11
166	International Guillainâ€BarrÃ© Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillainâ€BarrÃ© syndrome. Journal of the Peripheral Nervous System, 2017, 22, 68-76.	3.1	89
167	Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease. Neurology, 2017, 88, 2302-2309.	1.1	169
168	Modelling amyotrophic lateral sclerosis: progress and possibilities. DMM Disease Models and Mechanisms, 2017, 10, 537-549.	2.4	156
169	Progranulin functions as a cathepsin D chaperone to stimulate axonal outgrowth in vivo. Human Molecular Genetics, 2017, 26, 2850-2863.	2.9	111
170	Finger extension weakness and downbeat nystagmus motor neuron disease syndrome: A novel motor neuron disorder?. Muscle and Nerve, 2017, 56, 1164-1168.	2.2	14
171	Screening for lipoprotein receptor-related protein 4-, agrin-, and titin-antibodies and exploring the autoimmune spectrum in myasthenia gravis. Journal of Neurology, 2017, 264, 1193-1203.	3.6	41
172	Identification and characterization of Nanobodies targeting the EphA4 receptor. Journal of Biological Chemistry, 2017, 292, 11452-11465.	3.4	23
173	Negative commercial screening test for paraneoplastic antibodies in a case of opsoclonus. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e329.	6.0	1
174	Randomized crossâ€over trial of ventilator modes during nonâ€invasive ventilation titration in amyotrophic lateral sclerosis. Respirology, 2017, 22, 1212-1218.	2.3	20
175	Phase Separation of C9orf72 Dipeptide Repeats Perturbs Stress Granule Dynamics. Molecular Cell, 2017, 65, 1044-1055.e5.	9.7	437
176	Genetic correlation between amyotrophic lateral sclerosis and schizophrenia. Nature Communications, 2017, 8, 14774.	12.8	114
177	Positron emission tomography in amyotrophic lateral sclerosis: Towards targeting of molecular pathological hallmarks. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 533-547.	6.4	7
178	TBK1 Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. Human Mutation, 2017, 38, 297-309.	2.5	87
179	IgG4 autoantibodies against muscle-specific kinase undergo Fab-arm exchange in myasthenia gravis patients. Journal of Autoimmunity, 2017, 77, 104-115.	6.5	92
180	Development of Improved HDAC6 Inhibitors as Pharmacological Therapy for Axonal Charcotâ€“Marieâ€“Tooth Disease. Neurotherapeutics, 2017, 14, 417-428.	4.4	67

#	Article	IF	Citations
181	Defining Y-SNP variation among the Flemish population (Western Europe) by full genome sequencing. Forensic Science International: Genetics, 2017, 31, e12-e16.	3.1	6
182	July 2017 ENCALS statement on edaravone. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 471-474.	1.7	41
183	HDAC6 inhibition reverses axonal transport defects in motor neurons derived from FUS-ALS patients. Nature Communications, 2017, 8, 861.	12.8	275
184	Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurology, The, 2017, 16, 976-986.	10.2	472
185	Another piece in the progranulin puzzle: special binding between progranulin and prosaposin creates additional lysosomal access. Journal of Neurochemistry, 2017, 143, 154-157.	3.9	1
186	Sporadic late-onset nemaline myopathy: clinico-pathological characteristics and review of 76 cases. Orphanet Journal of Rare Diseases, 2017, 12, 86.	2.7	77
187	Diagnostic Challenges and Clinical Characteristics of Hepatitis E Virusâ€“Associated Guillain-BarrÃ© Syndrome. JAMA Neurology, 2017, 74, 26.	9.0	61
188	Targeted Genetic Screen in Amyotrophic Lateral Sclerosis Reveals Novel Genetic Variants with Synergistic Effect on Clinical Phenotype. Frontiers in Molecular Neuroscience, 2017, 10, 370.	2.9	24
189	Metabolic Syndrome, Neurotoxic 1-Deoxysphingolipids and Nervous Tissue Inflammation in Chronic Idiopathic Axonal Polyneuropathy (CIAP). PLoS ONE, 2017, 12, e0170583.	2.5	13
190	Genetic ablation of IP3receptor 2 increases cytokines and decreases survival ofSOD1G93Amice. Human Molecular Genetics, 2016, 25, 3491-3499.	2.9	19
191	Cost of Illness Study In Patients With Myasthenia Gravis Treated With Plasma Exchange Therapy In Belgium. Value in Health, 2016, 19, A592.	0.3	0
192	RNA Sequencing Analysis of Intracranial Aneurysm Walls Reveals Involvement of Lysosomes and Immunoglobulins in Rupture. Stroke, 2016, 47, 1286-1293.	2.0	55
193	Myasthenia gravis with muscle specific kinase antibodies mimicking amyotrophic lateral sclerosis. Neuromuscular Disorders, 2016, 26, 350-353.	0.6	24
194	A mapping review of international guidance on the management and care of amyotrophic lateral sclerosis (ALS). Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 325-336.	1.7	14
195	Multicenter validation of CSF neurofilaments as diagnostic biomarkers for ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 404-413.	1.7	84
196	Patient-ventilator asynchrony, leaks and sleep in patients with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 343-350.	1.7	10
197	Gain of Toxicity from ALS/FTD-Linked Repeat Expansions in C9ORF72 Is Alleviated by Antisense Oligonucleotides Targeting GGGGCC-Containing RNAs. Neuron, 2016, 90, 535-550.	8.1	437
198	Awaji criteria improves the diagnostic sensitivity in amyotrophic lateral sclerosis: A systematic review using individual patient data. Clinical Neurophysiology, 2016, 127, 2684-2691.	1.5	74

#	Article	IF	Citations
199	Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: A history of statins and experience from a large international multi-center study. Autoimmunity Reviews, 2016, 15, 983-993.	5.8	105
200	Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nature Genetics, 2016, 48, 1043-1048.	21.4	494
201	NEK1 variants confer susceptibility to amyotrophic lateral sclerosis. Nature Genetics, 2016, 48, 1037-1042.	21.4	218
202	Drosophila screen connects nuclear transport genes to DPR pathology in c9ALS/FTD. Scientific Reports, 2016, 6, 20877.	3.3	239
203	Database crossing allows better understanding of neuromuscular disorders epidemiology: The Belgian example. Neuromuscular Disorders, 2016, 26, S207.	0.6	0
204	Inside out: the role of nucleocytoplasmic transport in ALS and FTLD. Acta Neuropathologica, 2016, 132, 159-173.	7.7	109
205	Association of a Locus in theCAMTA1Gene With Survival in Patients With Sporadic Amyotrophic Lateral Sclerosis. JAMA Neurology, 2016, 73, 812.	9.0	57
206	Clinical features ofTBK1carriers compared withC9orf72,GRNand non-mutation carriers in a Belgian cohort. Brain, 2016, 139, 452-467.	7.6	86
207	Prospective Validation of ¹⁸F-FDG Brain PET Discriminant Analysis Methods in the Diagnosis of Amyotrophic Lateral Sclerosis. Journal of Nuclear Medicine, 2016, 57, 1238-1243.	5.0	44
208	Possible influence of <scp>AMPD</scp>1 on cholinergic neurotransmission and sleep. Journal of Sleep Research, 2016, 25, 124-126.	3.2	0
209	How robust is ACTIVLIM for the follow-up of activity limitations in patients with neuromuscular diseases?. Neuromuscular Disorders, 2016, 26, 211-220.	0.6	16
210	A large-scale multicentre cerebral diffusion tensor imaging study in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 570-579.	1.9	138
211	Acute ataxic neuropathy associated with hepatitis E virus infection. Muscle and Nerve, 2015, 52, 464-465.	2.2	9
212	Noninvasive Ventilation Improves Sleep in Amyotrophic Lateral Sclerosis: A Prospective Polysomnographic Study. Journal of Clinical Sleep Medicine, 2015, 11, 559-566.	2.6	72
213	140th Annual Meeting American Neurological Association. Annals of Neurology, 2015, 78, S1-S242.	5.3	10
214	FDG-PET findings in three cases of Millsâ€™ syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 87, jnnp-2014-309952.	1.9	7
215	Genetic Creutzfeldt-Jakob disease mimicking chronic inflammatory demyelinating polyneuropathy. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e173.	6.0	5
216	Restoration of Progranulin Expression Rescues Cortical Neuron Generation in an Induced Pluripotent Stem Cell Model of Frontotemporal Dementia. Stem Cell Reports, 2015, 4, 16-24.	4.8	62

#	Article	IF	Citations
217	The neonatal sarcoplasmic reticulum Ca2+-ATPase gives a clue to development and pathology in human muscles. Journal of Muscle Research and Cell Motility, 2015, 36, 195-203.	2.0	6
218	Early stages of building a rare disease registry, methods and 2010 data from the Belgian Neuromuscular Disease Registry (BNMDR). Acta Neurologica Belgica, 2015, 115, 97-104.	1.1	19
219	A 62-Year-Old Woman with Muscle Weakness. Clinical Chemistry, 2015, 61, 1133-1135.	3.2	3
220	Loss of TBK1 is a frequent cause of frontotemporal dementia in a Belgian cohort. Neurology, 2015, 85, 2116-2125.	1.1	151
221	Unraveling the genetic landscape of autosomal recessive Charcot-Marie-Tooth neuropathies using a homozygosity mapping approach. Neurogenetics, 2015, 16, 33-42.	1.4	29
222	Peripheral progranulin levels do not reflect brain progranulin levels. Future Neurology, 2014, 9, 521-524.	0.5	1
223	Value of¹⁸Fluorodeoxyglucoseâ€“Positron-Emission Tomography in Amyotrophic Lateral Sclerosis. JAMA Neurology, 2014, 71, 553.	9.0	111
224	Analysis of the KIFAP3 gene in amyotrophic lateral sclerosis: a multicenter survival study. Neurobiology of Aging, 2014, 35, 2420.e13-2420.e14.	3.1	16
225	A phase IIâ^'III trial of olesoxime in subjects with amyotrophic lateral sclerosis. European Journal of Neurology, 2014, 21, 529-536.	3.3	104
226	Rotavirus vaccination in Europe: drivers and barriers. Lancet Infectious Diseases, The, 2014, 14, 416-425.	9.1	72
227	Granzyme M targets topoisomerase II alpha to trigger cell cycle arrest and caspase-dependent apoptosis. Cell Death and Differentiation, 2014, 21, 416-426.	11.2	19
228	A genome-wide association meta-analysis identifies a novel locus at 17q11.2 associated with sporadic amyotrophic lateral sclerosis. Human Molecular Genetics, 2014, 23, 2220-2231.	2.9	123
229	Exome sequencing reveals HINT1 mutations as a cause of distal hereditary motor neuropathy. European Journal of Human Genetics, 2014, 22, 847-850.	2.8	33
230	G.P.253. Neuromuscular Disorders, 2014, 24, 893.	0.6	0
231	G.P.3. Neuromuscular Disorders, 2014, 24, 795.	0.6	2
232	No evidence for shared genetic basis of common variants in multiple sclerosis and amyotrophic lateral sclerosis. Human Molecular Genetics, 2014, 23, 1916-1922.	2.9	23
233	T.P.39. Neuromuscular Disorders, 2014, 24, 905-906.	0.6	0
234	Prevention of intestinal obstruction reveals progressive neurodegeneration in mutant TDP-43 (A315T)mice. Molecular Neurodegeneration, 2014, 9, 24.	10.8	56

#	Article	IF	Citations
235	Sequencing an Ashkenazi reference panel supports population-targeted personal genomics and illuminates Jewish and European origins. Nature Communications, 2014, 5, 4835.	12.8	156
236	<scp>C9orf72</scp> and <scp>UNC13A</scp> are shared risk loci for amyotrophic lateral sclerosis and frontotemporal dementia: A genomeâ€wide metaâ€analysis. Annals of Neurology, 2014, 76, 120-133.	5.3	91
237	Rare mutations in SQSTM1 modify susceptibility to frontotemporal lobar degeneration. Acta Neuropathologica, 2014, 128, 397-410.	7.7	93
238	Developments in treatments for amyotrophic lateral sclerosis via intracerebroventricular or intrathecal delivery. Expert Opinion on Investigational Drugs, 2014, 23, 955-963.	4.1	12
239	Multicentre quality control evaluation of different biomarker candidates for amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2014, 15, 344-350.	1.7	62
240	Hdac6 deletion delays disease progression in the SOD1G93A mouse model of ALS. Human Molecular Genetics, 2013, 22, 1783-1790.	2.9	122
241	Rapamycin increases survival in ALS mice lacking mature lymphocytes. Molecular Neurodegeneration, 2013, 8, 31.	10.8	58
242	Age of onset of amyotrophic lateral sclerosis is modulated by a locus on 1p34.1. Neurobiology of Aging, 2013, 34, 357.e7-357.e19.	3.1	69
243	Frequency of C9orf72 repeat expansions in amyotrophic lateral sclerosis: a Belgian cohort study. Neurobiology of Aging, 2013, 34, 2890.e7-2890.e12.	3.1	38
244	APP Processing in Human Pluripotent Stem Cell-Derived Neurons Is Resistant to NSAID-Based Î³-Secretase Modulation. Stem Cell Reports, 2013, 1, 491-498.	4.8	58
245	Genetic ablation of phospholipase C delta 1 increases survival in SOD1G93A mice. Neurobiology of Disease, 2013, 60, 11-17.	4.4	18
246	Progranulin does not affect motor neuron degeneration in mutant SOD1 mice and rats. Neurobiology of Aging, 2013, 34, 2302-2303.	3.1	11
247	H63D polymorphism in HFE is not associated with amyotrophic lateral sclerosis. Neurobiology of Aging, 2013, 34, 1517.e5-1517.e7.	3.1	19
248	The neurotrophic properties of progranulin depend on the granulin E domain but do not require sortilin binding. Neurobiology of Aging, 2013, 34, 2541-2547.	3.1	63
249	Oligodendrocyte dysfunction in the pathogenesis of amyotrophic lateral sclerosis. Brain, 2013, 136, 471-482.	7.6	205
250	The C9ORF72 expansion mutation is a common cause of ALS+/â^'FTD in Europe and has a single founder. European Journal of Human Genetics, 2013, 21, 102-108.	2.8	201
251	Clinical implications of recent breakthroughs in amyotrophic lateral sclerosis. Current Opinion in Neurology, 2013, 26, 466-472.	3.6	22
252	Non-invasive ventilation in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 85-95.	1.7	20

#	Article	IF	Citations
253	Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes (MELAS) Syndrome Mimicking Herpes Simplex Encephalitis on Imaging Studies. Journal of Computer Assisted Tomography, 2013, 37, 279-281.	0.9	13
254	Beta-2 microglobulin is important for disease progression in a murine model for amyotrophic lateral sclerosis. Frontiers in Cellular Neuroscience, 2013, 7, 249.	3.7	20
255	Whole-genome sequencing reveals a coding non-pathogenic variant tagging a non-coding pathogenic hexanucleotide repeat expansion in C9orf72 as cause of amyotrophic lateral sclerosis. Human Molecular Genetics, 2012, 21, 2412-2419.	2.9	33
256	Loss-of-function mutations in HINT1 cause axonal neuropathy with neuromyotonia. Nature Genetics, 2012, 44, 1080-1083.	21.4	102
257	From El Escorial to Awaji: where do we go next with the amyotrophic lateral sclerosis criteria?. Neurodegenerative Disease Management, 2012, 2, 135-140.	2.2	0
258	Polymorphisms in the GluR2 gene are not associated with amyotrophic lateral sclerosis. Neurobiology of Aging, 2012, 33, 418-420.	3.1	8
259	UNC13A is a modifier of survival in amyotrophic lateral sclerosis. Neurobiology of Aging, 2012, 33, 630.e3-630.e8.	3.1	107
260	Dantrolene is neuroprotective in vitro, but does not affect survival in SOD1G93A mice. Neuroscience, 2012, 220, 26-31.	2.3	18
261	EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans. Nature Medicine, 2012, 18, 1418-1422.	30.7	269
262	NIPA1 polyalanine repeat expansions are associated with amyotrophic lateral sclerosis. Human Molecular Genetics, 2012, 21, 2497-2502.	2.9	49
263	Neuronal overexpression of IP3 receptor 2 is detrimental in mutant SOD1 mice. Biochemical and Biophysical Research Communications, 2012, 429, 210-213.	2.1	12
264	EFNS guidelines on the Clinical Management of Amyotrophic Lateral Sclerosis (MALS) â€“ revised report of an EFNS task force. European Journal of Neurology, 2012, 19, 360-375.	3.3	860
265	Expanded ATXN2 CAG repeat size in ALS identifies genetic overlap between ALS and SCA2. Neurology, 2011, 76, 2066-2072.	1.1	151
266	Towards a neuroimaging biomarker for amyotrophic lateral sclerosis. Lancet Neurology, The, 2011, 10, 400-403.	10.2	156
267	G37R SOD1 mutant alters mitochondrial complex I activity, Ca2+ uptake and ATP production. Cell Calcium, 2011, 49, 217-225.	2.4	54
268	HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1â€“induced Charcot-Marie-Tooth disease. Nature Medicine, 2011, 17, 968-974.	30.7	405
269	Cellular Effects of Progranulin in Health and Disease. Journal of Molecular Neuroscience, 2011, 45, 549-560.	2.3	98
270	Benefit of the Awaji diagnostic algorithm for amyotrophic lateral sclerosis: A prospective study. Annals of Neurology, 2011, 70, 79-83.	5.3	85

#	Article	IF	Citations
271	Angiogenin variants in Parkinson disease and amyotrophic lateral sclerosis. Annals of Neurology, 2011, 70, 964-973.	5.3	168
272	Amyloid precursor protein mutation E682K at the alternative Î²â€secretase cleavage Î²â€²â€site increases AÎ² generation. EMBO Molecular Medicine, 2011, 3, 291-302.	6.9	97
273	Microglial Upregulation of Progranulin as a Marker of Motor Neuron Degeneration. Journal of Neuropathology and Experimental Neurology, 2010, 69, 1191-1200.	1.7	64
274	Chromosome 9p21 in sporadic amyotrophic lateral sclerosis in the UK and seven other countries: a genome-wide association study. Lancet Neurology, The, 2010, 9, 986-994.	10.2	205
275	The occurrence of mutations in FUS in a Belgian cohort of patients with familial ALS. European Journal of Neurology, 2010, 17, 754-756.	3.3	41
276	Pathogenic cysteine mutations affect progranulin function and production of mature granulins. Journal of Neurochemistry, 2010, 112, 1305-1315.	3.9	76
277	The neurobiology of amyotrophic lateral sclerosis. European Journal of Neuroscience, 2010, 31, 2247-2265.	2.6	78
278	Progranulin is Neurotrophic In Vivo and Protects against a Mutant TDP-43 Induced Axonopathy. PLoS ONE, 2010, 5, e13368.	2.5	127
279	An unusual presentation of Guillain-Barre syndrome associated with monospecific anti-GD1b antibodies. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 587-588.	1.9	1
280	Microbleeds and the Risk of Recurrent Stroke. Stroke, 2010, 41, 2005-2009.	2.0	87
281	Tau levels do not influence human ALS or motor neuron degeneration in the SOD1 ^{G93A} mouse. Neurology, 2010, 74, 1687-1693.	1.1	18
282	Mutations in SACS cause atypical and late-onset forms of ARSACS. Neurology, 2010, 75, 1181-1188.	1.1	114
283	VEGF protects motor neurons against excitotoxicity by upregulation of GluR2. Neurobiology of Aging, 2010, 31, 2185-2191.	3.1	78
284	Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncology, The, 2010, 11, 1086-1095.	10.7	187
285	TDP-43 M311V mutation in familial amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 354-355.	1.9	49
286	Proteomics analyses reveal the evolutionary conservation and divergence of N-terminal acetyltransferases from yeast and humans. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 8157-8162.	7.1	472
287	Structure of granzyme C reveals an unusual mechanism of protease autoinhibition. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 5587-5592.	7.1	25
288	Autosomal recessive spastic ataxia of Charlevoix-Saguenay. Neurology, 2009, 72, 1790-1790.	1.1	13

#	Article	IF	Citations
289	Serum biomarker for progranulinâ€associated frontotemporal lobar degeneration. Annals of Neurology, 2009, 65, 603-609.	5.3	195
290	Benefits of intensive insulin therapy on neuromuscular complications in routine daily critical care practice: a retrospective study. Critical Care, 2009, 13, R5.	5.8	47
291	Recent advances in motor neuron disease. Current Opinion in Neurology, 2009, 22, 486-492.	3.6	56
292	The role of AMPA receptors and VEGF in ALS. Verhandelingen - Koninklijke Academie Voor Geneeskunde Van BelgiÃ«, 2009, 71, 241-50.	0.2	1
293	Novel Role for Vascular Endothelial Growth Factor (VEGF) Receptor-1 and Its Ligand VEGF-B in Motor Neuron Degeneration. Journal of Neuroscience, 2008, 28, 10451-10459.	3.6	119
294	Progranulin genetic variability contributes to amyotrophic lateral sclerosis. Neurology, 2008, 71, 253-259.	1.1	148
295	Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival. Journal of Cell Biology, 2008, 181, 37-41.	5.2	376
296	Astrocytes regulate GluR2 expression in motor neurons and their vulnerability to excitotoxicity. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 14825-14830.	7.1	193
297	Role of mitochondria in kainate-induced fast Ca2+ transients in cultured spinal motor neurons. Cell Calcium, 2007, 42, 59-69.	2.4	53
298	Ivermectin inhibits AMPA receptor-mediated excitotoxicity in cultured motor neurons and extends the life span of a transgenic mouse model of amyotrophic lateral sclerosis. Neurobiology of Disease, 2007, 25, 8-16.	4.4	46
299	The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2006, 1762, 1068-1082.	3.8	385
300	Vascular endothelial growth factor in amyotrophic lateral sclerosis and other neurodegenerative diseases. Muscle and Nerve, 2006, 34, 391-405.	2.2	38
301	GluR2 Deficiency Accelerates Motor Neuron Degeneration in a Mouse Model of Amyotrophic Lateral Sclerosis. Journal of Neuropathology and Experimental Neurology, 2005, 64, 605-612.	1.7	104
302	Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nature Neuroscience, 2005, 8, 85-92.	14.8	464
303	Excitotoxicity and Amyotrophic Lateral Sclerosis. Neurodegenerative Diseases, 2005, 2, 147-159.	1.4	132
304	Long-lasting changes in GABA responsiveness in cultured neurons. Neuroscience Letters, 2004, 365, 69-72.	2.1	7
305	The AMPA receptor antagonist NBQX prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis. Neuroscience Letters, 2003, 343, 81-84.	2.1	115
306	Chapter 10 Excitotoxicity and Oxidative Stress in Pathogenesis of Amyotrophic Lateral Sclerosis/Motor Neuron Disease. Blue Books of Practical Neurology, 2003, 28, 259-cp1.	0.1	1

#	Article	IF	Citations
307	Chloride Influx Aggravates Ca2+-Dependent AMPA Receptor-Mediated Motoneuron Death. Journal of Neuroscience, 2003, 23, 4942-4950.	3.6	47
308	Upregulation of HSP27 in a Transgenic Model of ALS. Journal of Neuropathology and Experimental Neurology, 2002, 61, 968-974.	1.7	87
309	An Î±-mercaptoacrylic acid derivative (PD150606) inhibits selective motor neuron death via inhibition of kainate-induced Ca2+ influx and not via calpain inhibition. Neuropharmacology, 2002, 42, 706-713.	4.1	51
310	GluR2-Dependent Properties of AMPA Receptors Determine the Selective Vulnerability of Motor Neurons to Excitotoxicity. Journal of Neurophysiology, 2002, 88, 1279-1287.	1.8	124
311	Na+ Entry Through AMPA Receptors Results in Voltage-Gated K+ Channel Blockade in Cultured Rat Spinal Cord Motoneurons. Journal of Neurophysiology, 2002, 88, 965-972.	1.8	15
312	PET Imaging in ALS. , 0, , .		2
313	Genome-Wide Analyses Identify KIF5A as a Novel ALS Gene. SSRN Electronic Journal, 0, , .	0.4	4